[2016/05/31] InnoPharmax will participate in ASCO Annual Meeting 2016 in Chicago (Booth No. 21096)
Taipei, Taiwan, R.O.C. – InnoPharmax Inc. announced that the Company is going to participate the exhibition (booth No. 21096) at the 2016 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, USA.  The meeting will be held from June 3 through June 7, 2016 and the exhibition will be from June 4 through June 6.

 

 

The following information will be presented:

 

l   OralPAS Technology Platform

l   US FDA Orphan Drug Designation in the Treatment of Cholangiocarcinoma

l   GemOral in the Treatment of Cholangiocarcinoma

 

About Gemcitabine hydrochloride oral formulation (GemOral®)

 

Gemcitaine (2',2'-difluorodeoxycytidine) is a fluorine-substituted deoxycytidine analog with a broad spectrum of antitumor activity.  It is rapidly and extensively deaminated by cytidine deaminase to the inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU).  It has been reported in a reported clinical study that the systemic exposure to oral gemcitabine was low due to extensive first pass metabolism to dFdU. 

 

GemOral® was developed based on InnoPharmax's proprietary formulations. Lower dose is designed with novel oral formulation due to metronomic chemotherapy consideration (frequently administration with low dose). By metronomic chemotherapy, GemOral® can reduces the level of toxicity significantly. GemOral® can be submitted through 505(b)(2) pathway, which offers a unique opportunity for rapid approval.

 

Up to date, the clinical data of GemOral® has been shown its better pharmacokinetic characteristics. Due to its new administration route and unique formulation, GemOral® has been shown its clinical benefits in several new indications with promising in-vivo data.

 

 

About InnoPharmax

 

InnoPharmax is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology and oncology. It develops and acquires potential drug candidates for further development as well as commercialization, and uses internally developed drug delivery technology platforms for improving the safety and effectiveness of currently available drugs to provide better medical choices in these specific disease categories.

回上頁

優吉兒網站設計 - Website Info.